Healthcare / BiotechnologyNasdaqGS
$5.65
-0.30 (-5.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-60.6M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$433M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-59.2%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
-31.7%
FCF CAGR
—
FCF margin
-3995.3%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.0M · net income $-48.8M · FCF $-40.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $1.0M | $1.0M | $5.7M | $1.7M | $652000.00 | $30.0M | $9.9M | $9.9M |
| Net Income | $-48.8M | $-48.8M | $-75.4M | $-87.3M | $-101.9M | $-45.0M | $-36.6M | $-24.0M |
| EBITDA | $-47.8M | $-47.8M | $-76.7M | $-87.9M | $-100.3M | $-43.9M | $-36.3M | $-24.6M |
| EPS | — | — | -1.49 | -2.05 | -2.41 | -1.07 | -2.36 | — |
| Operating Margin | -5150.8% | -5150.8% | -1408.3% | -5549.6% | -15848.0% | -150.8% | -371.8% | -253.5% |
| Net Margin | -4880.9% | -4880.9% | -1318.1% | -5268.4% | -15635.7% | -149.8% | -368.5% | -242.6% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | — | — | — |
| Current Ratio | 22.07 | 22.07 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-40.0M | $-40.0M | $-60.6M | $-81.6M | $-106.1M | $-65.0M | $-34.4M | $-21.4M |
| Returns | ||||||||
| ROE | -59.2% | -59.2% | -94.7% | -60.3% | -57.9% | -16.5% | -11.8% | 69.4% |
| Valuation | ||||||||
| P/B | 4.34 | 4.34 | 0.85 | 2.43 | 0.70 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -82.5% | -82.5% | 245.3% | 154.1% | — | 202.2% | 0.5% | — |
| EPS Growth | — | — | 27.3% | 14.9% | — | 54.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+459.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.49 → n/d
Residual
+459.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.